Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

6 recruiting

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 3
1(33.3%)
3Total
N/A(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT05055648Phase 3Recruiting

PROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy

Role: collaborator

NCT04648462Recruiting

Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology

Role: collaborator

NCT06180434Recruiting

Short Term Outcomes After PRoton and PhotoN RadiOtherapy for IDH Mutated Grade 2 and 3 Gliomas

Role: collaborator

NCT04304300Completed

Radiotherapy in IDH Mutated Glioma: Evaluation of Late Outcomes

Role: collaborator

NCT05364411Not ApplicableRecruiting

HYpofractionated, Dose-redistributed RAdiotherapy With Protons and Photons in HNSCC

Role: collaborator

NCT04832620Recruiting

Image Assisted Optimization of Proton Radiation Therapy in Chordomas and Chondrosarcomas

Role: collaborator

NCT05406856Not ApplicableRecruiting

PROTECT: On-line Adaptive Proton Therapy for Cervical Cancer

Role: collaborator

NCT03513042Terminated

Early Response Evaluation of Proton Therapy by PET-imaging in Squamous Cell Carcinoma Located in the Head and Neck

Role: collaborator

All 8 trials loaded